Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Clinical and Experimental Metastasis

Volumn 31, Issue 1, 2014, Pages 101-110

  Roque, Dana M ^a   Buza, Natalia ^a   Glasgow, Michelle ^a   Bellone, Stefania ^a   Bortolomai, Ileana ^a   Gasparrini, Sara ^a   Cocco, Emiliano ^a   Ratner, Elena ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Rutherford, Thomas J ^a   Schwartz, Peter E ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epothilone; Neoadjuvant chemotherapy; Ovarian cancer; Paclitaxel resistance; Tubulin

Indexed keywords

BETA TUBULIN; BIOLOGICAL MARKER; CARBOPLATIN; CLASS III BETA TUBULIN; EPOTHILONE B; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STROMA; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84893178411     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9614-5     Document Type: Article

References (53)

1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Benedetti-Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med 363:943-953
2. Kang S, Nam BH (2009) Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 16:2315-2320
3. Crawford SC, Vasey PA, Paul J, Hay A, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23:8802-8811
4. Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE (2013) Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol 107(2):195-200
5. Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T (2011) Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J Gynecol Oncol 22(3):183-187
6. Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070-1076
7. Raspaglio G, Fillipetti F, Prislei F, Penci R, De Maria I, Cicchillitti K, Mozzetti S, Scambia G, Ferlini C (2008) Hypoxia induces class III beta-tubulin gene expression by HIF-1 alpha binding to its 3′ flanking region. Gene 409(1-2):100-108
8. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M (2006) The β-I/β-III- tubulin isoforms and their complexes with antimitotic agent: docking and molecular dynamics studies. FEBS J 273:3301-3310
9. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C (2012) Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 227:1034-1041
10. Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G (2007) Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 7(8):704-712
11. Sève P, Dumontet C, Reiman T (2010) Role of tubulin-β-III in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67(2):136-143
12. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int J Cancer 120:2078-2085
13. Mariani M, Zannoni G, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C (2012) Gender influences the Class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 18(10):2964-2975
14. Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR (2007) Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27-34
15. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333
16. Tavassoli FA, Devilee P (2003) World Health Organization: Tumours of the Breast and Female Genital Organs. IARC Press, Lyon
17. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102(1):134-143
18. Tassi RA, Bignotti E, Rossi E (2007) Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol 105:578-585
19. Carrara L, Guzzo F, Roque DM, Bellone S, Cocco E, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD (2012) Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecol Oncol 125(1):231-236
20. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti F, Ferrandina G, Scambia G (2005) Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298-305
21. Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD (2013) Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. doi: 10.1002/cncr.28017
22. Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD (2013) Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol. doi: 10.1016/ajog.2013.04.017
23. Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F (2008) Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 27(2):207-212
24. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE (2004) Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 3:960-969
25. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71:431-436
26. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS (2008) The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 108:287-292
27. Aletti GD, Dowdy SC, Podratz KC, Cliby WA (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100:283-287
28. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259
29. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559-564
30. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multi- center trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234-1244
31. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282-1293
32. Mozzetti S, Ferlini C, Concolino P, Filippetti, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11(1):298-305
33. Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C (2011) Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med 11:726-731
34. Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P, Thongsuksai P (2011) Differential protein expression in primary breast cancer and match axillary node metastasis. Oncol Rep 26(1):185-189
35. Kang CH, Jang BG, Kim D-W, Chung DH, Kim YT, Jheon S, Sung S-W, Hyun J (2009) Differences in the expression profiles of excision repair cross complementation group 1, X-ray repair crosscomplementation group 1, and β-III tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thoracic Oncol 4(11):1307-1312
36. van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, Vergote I (1997) A scoring system for immunohistochemical staining: concensus report of the task force for basic research of the EORTC-GCCG. J Clin Pathol 50:801-804
37. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C (2006) Class III β-Tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12:2774-2789
38. Chefetz I, AlveroAB Holberg JC, Lebowitz N, Craveiro V, Yang-Hatwich Y, Yin G, Squillace L, Sorteras M, Aldo P, Mor G (2013) TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 12(3):511-521
39. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G (2005) The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 65:2397-2405
40. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR (1998) Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77:562-566
41. Del Carmen MG, Birrer M, Shorge JO (2012) Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 127:652-661
42. Moller KA, Gehrig PA, Van Le L, Secord AA, Schorge J (2004) The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 94(1):170-174
43. Resnik E, Taxy JB (1996) Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 62(1):123-127
44. Le TD, Yamada SD, Rutgers JL, DiSaia PJ (1999) Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 73(3):461-463
45. Gan PP, Pasquier E, Kavallaris M (2007) Class III tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer. Cancer Res 67:9356-9936
46. Gan PP, McCarroll JA, Byrne FL, Garner J, Kavallaris M (2011) Specific-b-III tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 6(6):e21717
47. Pusztai L (2007) Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol Suppl 12:xii15-20
48. De Geest K, Blessing JA, Morris RT, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE (2009) Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 28:149-153
49. Dizon DS, Blessing JA, McMeekin DS, Sharma SK, DiSilvestro P, Alvarez RD (2009) Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic Oncology Group Trial 129-P. J Clin Oncol 27:3104-3108
50. NIH Clinical Trials. Evaluation of carboplatin/paclitaxel/bevacizumab in the treatment of advanced stage endometrial carcinoma. http://clinicaltrials. gov/ct2/show/ NCT00513786. Accessed 02 January 2013
51. Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ (2007) Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small cell lung caner whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25(23):3448-3455
52. Spigel DR, Anthony Greco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD (2012) Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer 78(1):70-75
53. McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, ang Y, Schmelter T (2012) Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer 106(1):70-76